MedTrace Logo

Patients Treated in Real Life With VEnetoclax for WAldenström Macroglobulinemia

NCT06200220 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 45

Last updated 2024-01-10

No results posted yet for this study

Summary

Waldenström macroglobulinemia (WM) is an incurable disease. BCL2 antagonist, an important anti-apoptosys molecule, is already approved for the treatment of chronic lymphocytic leukemia (CLL) and acute myeloid leukemia. Recently, a clinical trial including 32 patients with WM treated with Venetoclax showed an overall response rates of 84% and a major response rate of 81%. However, there is no in real life data, in the french population, of the efficiency of Venetoclax in WM. The aim of our multicentric retrospective study is to evaluate the efficiency and tolerance of Venetoclax in WM.

Conditions

  • Waldenstrom's Macroglobulinaemia Refractory

Interventions

DRUG

Venetoclax

Observational study

Sponsors & Collaborators

  • Poitiers University Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-28
Primary Completion
2023-12-28
Completion
2025-12-01

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06200220 on ClinicalTrials.gov